| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
|
Purity: ≥98%
Diphenhydramine HCl is a potent and first-generation histamine H1 receptor antagonist and an antiemetic that is used in various allergic conditions such as rhinitis, urticaria and conjunctivitis. Diphenhydramine blocks sodium currents that are tetrodotoxin-sensitive (TTX-S) and tetrodotoxin-resistant (TTX-R), with K(d) values of 48 mM and 86 mM, respectively, at a holding potential of -80 mV. Diphenhydramine has little effect on the conductance-voltage curve for TTX-R sodium currents, but it shifts it in the depolarizing direction for TTX-S sodium currents.
| Molecular Formula |
C17H21NO
|
|---|---|
| Molecular Weight |
255.3547
|
| Exact Mass |
255.16
|
| Elemental Analysis |
C, 79.96; H, 8.29; N, 5.49; O, 6.27
|
| CAS # |
58-73-1
|
| Related CAS # |
Diphenhydramine hydrochloride; 147-24-0; 88637-37-0 (citrate); 7491-10-3 (salicylate)
|
| Appearance |
Liquid
|
| SMILES |
CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
|
| InChi Key |
ZZVUWRFHKOJYTH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3
|
| Chemical Name |
2-benzhydryloxy-N,N-dimethylethanamine
|
| Synonyms |
Diphenhydramine; Debendrin; Difenhydramine; Dabylen; PM255; PM-255; PM 255
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~391.6 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.79 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.79 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9162 mL | 19.5810 mL | 39.1619 mL | |
| 5 mM | 0.7832 mL | 3.9162 mL | 7.8324 mL | |
| 10 mM | 0.3916 mL | 1.9581 mL | 3.9162 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04175834 | Active Recruiting |
Drug: antihistamine | Multiple Sclerosis Infusion Reaction |
Providence Health & Services | February 5, 2020 | Phase 3 |
| NCT02037126 | Active Recruiting |
Drug: Diphenhydramine Drug: Psilocybin |
Cocaine-Related Disorders | University of Alabama at Birmingham |
May 2015 | Phase 2 |
| NCT04741139 | Active Recruiting |
Drug: Acetaminophen and Diphenhydramine Only Product |
Immune Thrombocytopenia | Baylor College of Medicine | September 2, 2021 | Phase 1 |
| NCT04109885 | Active Recruiting |
Drug: Paracervical injection Drug: prochlorperazine and diphenhydramine. (Standard Treatment) |
Pain Management Emergency Department |
Christian Fromm, MD | September 15, 2020 | Phase 2 |
| NCT04805073 | Recruiting | Drug: Promethazine Drug: Placebo |
Pruritus Pregnancy Related |
University of Florida | August 9, 2021 | Phase 4 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA